ArticleNeoplasia (New York, N.Y.)2006
Signaling from p53 to NF-kappa B determines the chemotherapy responsiveness of neuroblastoma.
Article in Neoplasia (New York, N.Y.), 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Molecular Profiling of Nasopharyngeal Carcinoma Using the AACR Project GENIE Repository.Cancers · 2025Article
- Chemotherapy: a double-edged sword in cancer treatment.Cancer immunology, immunotherapy : CII · 2022Review
- Rapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?Journal of clinical medicine research · 2016Article
- Article
- A novel radiation-induced p53 mutation is not implicated in radiation resistance via a dominant-negative effect.PloS one · 2014Article
- Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis.OncoTargets and therapy · 2014Review
- Inhibition of nuclear factor kappa-B signaling reduces growth in medulloblastoma in vivo.BMC cancer · 2011Article
- Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition.Cancer gene therapy · 2009Article
- New approaches to pharmacotherapy of tumors of the nervous system during childhood and adolescence.Pharmacology & therapeutics · 2009Review
- Neoplasia: the second decade.Neoplasia (New York, N.Y.) · 2008Article
- Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction.Neoplasia (New York, N.Y.) · 2008Article
- Active roles for inhibitory kappaB kinases alpha and beta in nuclear factor-kappaB-mediated chemoresistance to doxorubicin.Molecular cancer therapeutics · 2008Article
- Human neuroblastoma cells rapidly enter cell cycle arrest and apoptosis following exposure to C-28 derivatives of the synthetic triterpenoid CDDO.Cancer biology & therapy · 2008Article
- Chemosensitization in non-small cell lung cancer cells by IKK inhibitor occurs via NF-kappaB and mitochondrial cytochrome c cascade.Journal of cellular and molecular medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neuroblastic (N) type neuroblastoma (NB) is the predominant cell type in NB tumors. Previously, we determined that activated nuclear factor kappaB (NF-kappaB) is required for doxorubicin and etoposide to kill N-type NB cells. This study was undertaken to determine how NF-kappaB is activated by these agents. The results show that p53 protein levels increase within 15 to 30 minutes of treatment. This increase occurs before the degradation of inhibitor of NF-kappaB (I-KB) alpha and the NF-kappaB-dependent activation of gene transcription. Moreover, p53 is necessary for NF-kappaB activation because cells with inactive p53 were resistant to NF-kappaB-mediated cell death. This pathway was further defined to show that p53 leads to the activation of MAPK/ERK activity kinase (MEK) 1 through a process that depends on protein synthesis and H-Ras. MEK1, in turn, mediates I-kappaB kinase activation. Together, these results demonstrate for the first time how NF-kappaB is activated in NB cells in response to conventional drugs. Furthermore, these findings provide an explanation as to why H-Ras expression correlates with a favorable prognosis in NB and identify intermediary signaling molecules that are targets for discovering treatments for NB that is resistant to conventional agents.
Indexed as
Identifiers
17215959PMC1764827What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.